Syncona says Achilles stake leaps to GBP145 million value after IPO
Syncona says Achilles stake leaps to GBP145 million value after IPO
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreThu, 11th Feb 2021 07:56
Syncona says Achilles stake leaps to GBP145 million value after IPO
Read more(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).
Read moreDIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares
Read moreSyncona invests USD42 million into Gyroscope to have 54% stake
Read more(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.
Read moreSyncona portfolio firm Achilles Therapeutics prices US share offering
Read moreTRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
Read moreIN BRIEF: Syncona investee Achilles Therapeutics files for US IPO
Read moreIN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test
Read moreSyncona Net Asset Value Dips In Third Quarter, Invests More In Quell
Read moreSyncona Investee Autolus Nets USD100 Million From ADS Offer
Read more(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).
Read moreSyncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback
Read moreSyncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read more